Flexion Therapeutics (FLXN) Stock Price Down 5.7%

Shares of Flexion Therapeutics Inc (NASDAQ:FLXN) traded down 5.7% during mid-day trading on Friday . The stock traded as low as $23.17 and last traded at $23.19. 633,012 shares changed hands during trading, a decline of 10% from the average session volume of 704,994 shares. The stock had previously closed at $24.58.

Several analysts have recently issued reports on the stock. Royal Bank of Canada set a $44.00 price target on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Sunday, October 29th. Berenberg Bank assumed coverage on shares of Flexion Therapeutics in a research report on Thursday, February 1st. They set a “buy” rating and a $42.00 price target on the stock. Northland Securities reissued a “buy” rating and set a $40.00 price target on shares of Flexion Therapeutics in a research report on Friday, November 10th. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Finally, ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $99.11.

The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87.

In other news, insider Neil Bodick bought 2,700 shares of Flexion Therapeutics stock in a transaction that occurred on Tuesday, November 21st. The shares were purchased at an average price of $24.49 per share, with a total value of $66,123.00. Following the completion of the acquisition, the insider now directly owns 64,605 shares in the company, valued at $1,582,176.45. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.98% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. Advisory Services Network LLC acquired a new stake in Flexion Therapeutics in the fourth quarter valued at approximately $108,000. Advisor Group Inc. raised its holdings in Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 3,500 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Flexion Therapeutics in the third quarter valued at approximately $135,000. IFP Advisors Inc raised its holdings in Flexion Therapeutics by 58.1% in the third quarter. IFP Advisors Inc now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $194,000 after acquiring an additional 2,950 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System purchased a new position in Flexion Therapeutics in the third quarter valued at approximately $235,000. 72.18% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Flexion Therapeutics (FLXN) Stock Price Down 5.7%” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://stocknewstimes.com/2018/02/18/flexion-therapeutics-flxn-stock-price-down-5-7.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply